Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.

Zhang Z, Zhang B, Wang X, Zhang X, Yang QX, Qing Z, Zhang W, Zhu D, Bi Y

Diabetes care21 May 2019Cited by 96 (Europe PMC)

PMID31221697DOI10.2337/dc18-2584PepBankPUB-31221697

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In obese adults with type 2 diabetes, 3 months of GLP-1 receptor agonist treatment (class-level) improved the MoCA score.
In plain wordsIn obese adults with diabetes, 3 months of GLP-1 receptor agonist drugs as a group improved a thinking test score.
Peptide
Liraglutide
Outcome
IncreaseMontreal Cognitive Assessment (MoCA) score
Study
n = 20
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
With 3-month GLP-1Ra treatment, obese subjects with diabetes exhibited improved Montreal Cognitive Assessment (MoCA) score, olfactory test total score, and enhanced odor-induced right parahippocampus activation.
1 context sentence(design, population, supporting numbers)
Summary · context
Among them, 20 obese individuals with diabetes with inadequate glycemic control and metformin monotherapy received GLP-1Ra treatment for 3 months and were reassessed for metabolic, cognitive, olfactory, and neuroimaging changes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3122169701
02HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In obese adults with type 2 diabetes, 3 months of GLP-1 receptor agonist treatment (class-level) improved the olfactory test total score.
In plain wordsIn obese adults with diabetes, 3 months of GLP-1 receptor agonist drugs as a group improved a smell test score.
Peptide
Liraglutide
Outcome
IncreaseOlfactory test total score
Study
n = 20
Outcome group
Sensory perception · Nervous system and cognition
Source sentences
Summary
With 3-month GLP-1Ra treatment, obese subjects with diabetes exhibited improved Montreal Cognitive Assessment (MoCA) score, olfactory test total score, and enhanced odor-induced right parahippocampus activation.
1 context sentence(design, population, supporting numbers)
Summary · context
Among them, 20 obese individuals with diabetes with inadequate glycemic control and metformin monotherapy received GLP-1Ra treatment for 3 months and were reassessed for metabolic, cognitive, olfactory, and neuroimaging changes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3122169702
03HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In obese adults with type 2 diabetes, 3 months of GLP-1 receptor agonist treatment (class-level) enhanced odor-induced right parahippocampus activation.
In plain wordsIn obese adults with diabetes, 3 months of GLP-1 receptor agonist drugs as a group increased brain activity in one region when smelling odors.
Peptide
Liraglutide
Outcome
IncreaseOdor-induced right parahippocampus activation
Study
n = 20
Outcome group
Brain and neuronal activity · Nervous system and cognition
Source sentences
Summary
With 3-month GLP-1Ra treatment, obese subjects with diabetes exhibited improved Montreal Cognitive Assessment (MoCA) score, olfactory test total score, and enhanced odor-induced right parahippocampus activation.
1 context sentence(design, population, supporting numbers)
Summary · context
Among them, 20 obese individuals with diabetes with inadequate glycemic control and metformin monotherapy received GLP-1Ra treatment for 3 months and were reassessed for metabolic, cognitive, olfactory, and neuroimaging changes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3122169703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT05313529

LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical Schooln = 3968 Oct 2022 to 1 Jul 2026

Type 2 Diabetes Mellitus · Mild Cognitive Impairment

Trial page ClinicalTrials.govUpdated 6 Aug 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.